ArticleCureus2025
Gyroscopic Radiosurgery for the Treatment of Trigeminal Neuralgia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadiosurgical treatment of trigeminal neuralgia (TN) is the most common functional radiosurgery procedure used to modulate refractory pain. The aim of this study is to describe the clinical results and dosimetric parameters of the first series of patients with TN treated with ZAP-X gyroscopic frameless radiosurgery (ZAP Surgical Systems, Inc., San Carlos, CA), an innovative, frameless radiosurgical device.
methodsA total of 30 patients with TN received gyroscopic frameless radiosurgery (GRS) between February 2023 and January 2025. Treatment plans were developed delivering a maximum dose of 90 Gy in a target that covered a 5-mm segment of the trigeminal nerve in the retrogasserian location using a single isocenter (5 mm collimator). Clinical and treatment information were analyzed with a specific focus on demographic characteristics, etiology, previous treatments, Barrow Institute (BNI) Pain Intensity Scale before and after GRS (pain relief response), the time to pain relief, and the rate of complications and recurrences.
results30 patients (21 females and 9 males) with a median age of 66 years (range: 31-92 years) underwent GRS for refractory TN. The median time from first diagnosis to GRS was 4 years (range: 6 months to 18 years). All patients had received a first therapeutic pharmacological line, 15 patients received at least a radiofrequency thermocoagulation, 7 patients received nerve blocks, 4 patients were treated with botox injection and 2 patients had previous radiosurgery. The median BNI Pain Intensity Scale before GRS was IV (range IIIa-V). The median treatment time was 37 minutes using a median of 221 beams. Median V12 and V10 of the brainstem were 0.04cc (range: 0-0.16cc) and 0.07cc (range: 0-0.24cc), respectively. The median BNI Pain Intensity Scale after GRS was II (range: I-VI) with 80% of patients reporting no pain or occasional pain without medication. The median time to pain relief was 15 days (range: 1-60 days). Five patients (16.6%) presented ipsilateral facial hypesthesia after GRS. 10% of patients presented with recurrent pain 2-6 months after GRS.
conclusionsGRS is a precise tool for treating TN, demonstrating safety and effectiveness in what is, to our knowledge, the first reported case series documenting its use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.